303 related articles for article (PubMed ID: 26901358)
1. Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.
French CE; McKenzie BC; Coope C; Rajanaidu S; Paranthaman K; Pebody R; Nguyen-Van-Tam JS; ; Higgins JP; Beck CR
Influenza Other Respir Viruses; 2016 Jul; 10(4):268-90. PubMed ID: 26901358
[TBL] [Abstract][Full Text] [Related]
2. Detection and control of a nosocomial respiratory syncytial virus outbreak in a stem cell transplantation unit: the role of palivizumab.
Kassis C; Champlin RE; Hachem RY; Hosing C; Tarrand JJ; Perego CA; Neumann JL; Raad II; Chemaly RF
Biol Blood Marrow Transplant; 2010 Sep; 16(9):1265-71. PubMed ID: 20304082
[TBL] [Abstract][Full Text] [Related]
3. Experience with the use of palivizumab together with infection control measures to prevent respiratory syncytial virus outbreaks in neonatal intensive care units.
Kurz H; Herbich K; Janata O; Sterniste W; Bauer K
J Hosp Infect; 2008 Nov; 70(3):246-52. PubMed ID: 18799241
[TBL] [Abstract][Full Text] [Related]
4. Monoclonal antibody for reducing the risk of respiratory syncytial virus infection in children.
Andabaka T; Nickerson JW; Rojas-Reyes MX; Rueda JD; Bacic Vrca V; Barsic B
Cochrane Database Syst Rev; 2013 Apr; (4):CD006602. PubMed ID: 23633336
[TBL] [Abstract][Full Text] [Related]
5. Nosocomial respiratory syncytial virus infections: the "Cold War" has not ended.
Hall CB
Clin Infect Dis; 2000 Aug; 31(2):590-6. PubMed ID: 10987726
[TBL] [Abstract][Full Text] [Related]
6. Use of palivizumab with other infection control measures to control respiratory syncytial virus outbreaks in neonatal care units.
Hammoud MS; Al-Taiar A; Raina A; Elsori D; Al-Qabandi S; Al-Essa M
J Trop Pediatr; 2016 Oct; 62(5):409-14. PubMed ID: 27118823
[TBL] [Abstract][Full Text] [Related]
7. Nosocomial respiratory syncytial virus infections in the palivizumab-prophylaxis era with implications regarding high-risk infants.
Ashkenazi-Hoffnung L; Dotan M; Livni G; Amir J; Bilavsky E
Am J Infect Control; 2014 Sep; 42(9):991-5. PubMed ID: 25179332
[TBL] [Abstract][Full Text] [Related]
8. Palivizumab and prevention of childhood respiratory syncytial viral infection: protocol for a systematic review and meta-analysis of breakthrough infections.
Jun S; Sebastianski M; Featherstone R; Robinson J
BMJ Open; 2019 Jul; 9(7):e029832. PubMed ID: 31340973
[TBL] [Abstract][Full Text] [Related]
9. Nosocomial transmission of respiratory syncytial virus in an outpatient cancer center.
Chu HY; Englund JA; Podczervinski S; Kuypers J; Campbell AP; Boeckh M; Pergam SA; Casper C
Biol Blood Marrow Transplant; 2014 Jun; 20(6):844-51. PubMed ID: 24607551
[TBL] [Abstract][Full Text] [Related]
10. Respiratory syncytial virus--is it preventable?
Ruuskanen O
J Hosp Infect; 1995 Jun; 30 Suppl():494-7. PubMed ID: 7560988
[TBL] [Abstract][Full Text] [Related]
11. Nosocomial respiratory syncytial virus infection in Canadian pediatric hospitals: a Pediatric Investigators Collaborative Network on Infections in Canada Study.
Langley JM; LeBlanc JC; Wang EE; Law BJ; MacDonald NE; Mitchell I; Stephens D; McDonald J; Boucher FD; Dobson S
Pediatrics; 1997 Dec; 100(6):943-6. PubMed ID: 9374561
[TBL] [Abstract][Full Text] [Related]
12. Nosocomial Respiratory Viral Infection in the Neonatal Intensive Care Unit.
Vain NE
Am J Perinatol; 2020 Sep; 37(S 02):S22-S25. PubMed ID: 32898879
[TBL] [Abstract][Full Text] [Related]
13. Immunoprophylaxis against respiratory syncytial virus (RSV) with palivizumab in children: a systematic review and economic evaluation.
Wang D; Cummins C; Bayliss S; Sandercock J; Burls A
Health Technol Assess; 2008 Dec; 12(36):iii, ix-x, 1-86. PubMed ID: 19049692
[TBL] [Abstract][Full Text] [Related]
14. Use of palivizumab to control an outbreak of syncytial respiratory virus in a neonatal intensive care unit.
Abadesso C; Almeida HI; Virella D; Carreiro MH; Machado MC
J Hosp Infect; 2004 Sep; 58(1):38-41. PubMed ID: 15350712
[TBL] [Abstract][Full Text] [Related]
15. Effectiveness of Palivizumab against Respiratory Syncytial Virus: Cohort and Case Series Analysis.
Moore HC; de Klerk N; Richmond PC; Fathima P; Xu R; Keil AD; Snelling TL; Strunk T
J Pediatr; 2019 Nov; 214():121-127.e1. PubMed ID: 31378522
[TBL] [Abstract][Full Text] [Related]
16. Successful prevention of respiratory syncytial virus nosocomial transmission following an enhanced seasonal infection control program.
Lavergne V; Ghannoum M; Weiss K; Roy J; Béliveau C
Bone Marrow Transplant; 2011 Jan; 46(1):137-42. PubMed ID: 20383207
[TBL] [Abstract][Full Text] [Related]
17. Molecular characteristics and successful management of a respiratory syncytial virus outbreak among pediatric patients with hemato-oncological disease.
Baier C; Haid S; Beilken A; Behnert A; Wetzke M; Brown RJP; Schmitt C; Ebadi E; Hansen G; Schulz TF; Pietschmann T; Bange FC
Antimicrob Resist Infect Control; 2018; 7():21. PubMed ID: 29449938
[TBL] [Abstract][Full Text] [Related]
18. RSV outbreak in a paediatric intensive care unit.
Thorburn K; Kerr S; Taylor N; van Saene HK
J Hosp Infect; 2004 Jul; 57(3):194-201. PubMed ID: 15236847
[TBL] [Abstract][Full Text] [Related]
19. Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients.
Garcia R; Raad I; Abi-Said D; Bodey G; Champlin R; Tarrand J; Hill LA; Umphrey J; Neumann J; Englund J; Whimbey E
Infect Control Hosp Epidemiol; 1997 Jun; 18(6):412-6. PubMed ID: 9181397
[TBL] [Abstract][Full Text] [Related]
20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group.
Pediatrics; 1998 Sep; 102(3 Pt 1):531-7. PubMed ID: 9738173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
